Mersana Therapeutics Inc Revenue Growth Rates (MRSN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Mersana Therapeutics inc   (NASDAQ: MRSN)
 

MRSN's Revenue Growth by Quarter and Year

Mersana Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MRSN Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September 11.01
2nd Quarter June 3.06
1st Quarter March 2.75
FY 16.82

MRSNs Annual Revenue
Mersana Therapeutics Inc 's Revenue in the fiscal year 2024 $ 40.50 millions
Mersana Therapeutics Inc 's Revenue in the fiscal year 2023 $ 36.86 millions
Mersana Therapeutics Inc 's Revenue in the fiscal year 2022 $ 26.58 millions
Mersana Therapeutics Inc 's Revenue in the fiscal year 2021 $ 0.04 millions
Mersana Therapeutics Inc 's Revenue in the fiscal year 2020 $ 0.83 millions




MRSN Revenue third quarter 2025 Y/Y Growth Comment
Mersana Therapeutics Inc reported fall in Revenue in the third quarter 2025 by -12.63% to $ 11.01 millions, from the same quarter in 2024.
The decline in the third quarter 2025 Mersana Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 1280.59%.

Looking into third quarter 2025 results within Major Pharmaceutical Preparations industry 10 other companies have achieved higher Revenue growth. While Mersana Therapeutics Inc ' s Revenue decrease of -12.63% ranks overall at the positon no. 53 in the third quarter 2025.


MRSN Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - 52.9 % -27.16 % 146800 %
3rd Quarter September -12.63 % 63.64 % 38.24 % 55600 %
2nd Quarter June 33.62 % -78.5 % 148.83 % 42700 %
1st Quarter March -70.27 % 18.59 % 282.35 % 20300 %
FY   - 9.91 % 38.64 % -

Financial Statements
Mersana Therapeutics Inc 's third quarter 2025 Revenue $ 11.01 millions MRSN's Income Statement
Mersana Therapeutics Inc 's third quarter 2024 Revenue $ 12.60 millions Quarterly MRSN's Income Statement


MRSN Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 29.84 % 38.96 % 163.73 %
3rd Quarter September 259.77 % 450.22 % -27.7 % 30.14 %
2nd Quarter June 11.27 % -75.24 % 36.54 % 109.8 %
1st Quarter March -83.19 % -13.55 % -46.9 % 20300 %
FY (Year on Year)   - 9.91 % 38.64 % -


Back to MRSN Growth rate Comparisons >> Back to MRSN Growth rate Comparisons >>


Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #11
Healthcare Sector #14
Overall #53

Revenue Y/Y Growth Statistics
High Average Low
20260 % 1280.59 % -98.62 %
(Mar 31 2022)   (Sep 30 2020)
Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #11
Healthcare Sector #14
Overall #53
Revenue Y/Y Growth Statistics
High Average Low
20260 % 1280.59 % -98.62 %
(Mar 31 2022)   (Sep 30 2020)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Mersana Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
20260 % 1280.59 % -98.62 %
(Mar 31 2022)  


MRSN's III. Quarter Q/Q Revenue Comment
Mersana Therapeutics inc achieved in the III. Quarter 2025 below company average Revenue doubling of 259.77% quarter on quarter, to $ 11.01 millions.

Within Major Pharmaceutical Preparations industry 10 other companies have achieved higher Revenue quarter on quarter growth. While Mersana Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 53.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #11
Healthcare Sector #14
Overall #53
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #11
Healthcare Sector #14
Overall #53
Revenue Q/Q Growth Statistics
High Average Low
20260 % 1280.59 % -98.62 %
(Mar 31 2022)  


MRSN's III. Quarter Q/Q Revenue Comment
Mersana Therapeutics inc achieved in the III. Quarter 2025 below company average Revenue doubling of 259.77% quarter on quarter, to $ 11.01 millions.

Within Major Pharmaceutical Preparations industry 10 other companies have achieved higher Revenue quarter on quarter growth. While Mersana Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 53.


Mersana Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)
Cumulative Revenue 12 Months Ending $ 33.18 $ 34.77 $ 34.01 $ 40.50 $ 34.84
Y / Y Revenue Growth (TTM) -4.76 % 16.14 % -11.21 % 9.88 % -14.7 %
Year on Year Revenue Growth Overall Ranking # 2667 # 2615 # 659 # 130 # 42
Seqeuential Revenue Change (TTM) -4.57 % 2.24 % -16.03 % 16.25 % 16.37 %
Seq. Revenue Growth (TTM) Overall Ranking # 703 # 2970 # 1677 # 1889 # 1431


Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2025 Mersana Therapeutics Inc reported a decrease in Revenue by -4.76% year on year, to $33 millions, compare to the 16.14% growth at Jun 30 2025.

In the Healthcare sector 364 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2615 to 2667.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 60
Healthcare Sector # 365
Overall # 2667

Revenue TTM Y/Y Growth Statistics
High Average Low
61716.28 %
 6244.24 %
-94.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 60
Sector # 149
S&P 500 # 703
Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2025 Mersana Therapeutics Inc reported a decrease in Revenue by -4.76% year on year, to $33 millions, compare to the 16.14% growth at Jun 30 2025.

In the Healthcare sector 364 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2615 to 2667.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 60
Healthcare Sector # 365
Overall # 2667

Revenue TTM Y/Y Growth Statistics
High Average Low
61716.28 %
6244.24 %
-94.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 60
Sector # 149
S&P 500 # 703




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MRSN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Sep 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2025
Community Health Systems Inc -0.10%$ -0.097 millions
Bioventus Inc -0.23%$ -0.232 millions
Bruker Corporation-0.39%$ -0.394 millions
Charles River Laboratories International inc -0.49%$ -0.486 millions
Protalix Biotherapeutics inc -0.60%$ -0.601 millions
Jaguar Health Inc -0.80%$ -0.804 millions
Bio techne Corp-1.01%$ -1.005 millions
Agilon Health Inc -1.08%$ -1.076 millions
Picard Medical Inc -1.25%$ -1.249 millions
Nexgel Inc -1.71%$ -1.709 millions
Capsovision Inc -1.75%$ -1.753 millions
Utah Medical Products Inc-2.02%$ -2.020 millions
10x Genomics Inc -2.04%$ -2.038 millions
Hyperfine Inc -2.06%$ -2.063 millions
Teladoc Health Inc -2.20%$ -2.197 millions
Lineage Cell Therapeutics Inc -2.59%$ -2.593 millions
Pacific Biosciences Of California Inc -2.83%$ -2.828 millions
Pluri Inc -3.07%$ -3.067 millions
Castle Biosciences Inc -3.19%$ -3.193 millions
Bionexus Gene Lab Corp -3.29%$ -3.291 millions
Nrc Health-3.38%$ -3.381 millions
Prestige Consumer Healthcare Inc -3.46%$ -3.459 millions
Sight Sciences Inc -3.57%$ -3.567 millions
Pediatrix Medical Group Inc -3.58%$ -3.577 millions
Quidelortho Corp-3.74%$ -3.741 millions
Escalon Medical Corp -3.81%$ -3.813 millions
Myriad Genetics Inc -3.98%$ -3.985 millions
Plus Therapeutics Inc -4.05%$ -4.052 millions
Perrigo Company Plc-4.07%$ -4.074 millions
P3 Health Partners Inc -4.66%$ -4.659 millions


About Mersana Therapeutics Inc Revenue Growth Rates (MRSN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Mersana Therapeutics Inc (CIK 1442836).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-25-052202
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Mersana Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.